{"id":934201,"date":"2026-02-04T16:08:26","date_gmt":"2026-02-04T21:08:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\/"},"modified":"2026-02-04T16:08:26","modified_gmt":"2026-02-04T21:08:26","slug":"relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\/","title":{"rendered":"Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., Feb.  04, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_gtLodn9M1OfMkCSMgd3fVjoH3RD8Pi2vx7weS_TB4Rlzzie55AvfyZFfpw7J_qXhiGe0RGtyYC7hpxEo1prJRoj8soW4dPyjjaDva25ODc=\" rel=\"nofollow\" target=\"_blank\">Relay Therapeutics, Inc.<\/a> (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 10:30 a.m. ET.<\/p>\n<p align=\"left\">The fireside chats will be webcast live and may be accessed through Relay Therapeutics\u2019 website under Events in the News &amp; Events section through the following link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RLhkxmejKue19zsJynV0JRb4Gd3hfdakg1LeaWCpXkTYMupn1dQ-Jhrx1PfLUO3bBI5IRZ8OaJDykgK-M_43tcLG-u4zQwRGNLMMOEeRRCDng5dO12Ul6YAGNddfj7oLqRQeUVweGuYO-9a6Ur3UaXImsj6zmr--czcufF8ZH5lsIS3_IHxM9oVLIfDAeruA\" rel=\"nofollow\" target=\"_blank\">https:\/\/ir.relaytx.com\/news-events\/events-presentations<\/a>. An archived replay of the webcast will be available for up to 30 days following the event.<\/p>\n<p align=\"left\">\n        <strong>About Relay Therapeutics<\/strong>\n      <\/p>\n<p align=\"left\">Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing\u00a0potentially life-changing therapies for\u00a0patients living with cancer and genetic disease. Relay&#8217;s Dynamo\u00ae platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company\u2019s lead clinical asset,\u00a0zovegalisib, is the first pan-mutant selective PI3K\u03b1 inhibitor to enter clinical development and\u00a0is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+\/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3K\u03b1-driven vascular anomalies. Relay&#8217;s\u00a0pipeline also includes programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RMzImKhmDB1KJgH2hDXnLZO_48JaeVlzLo73zmpwKbRdXbs9Ou4j7FFy4IkMCnOUNqdopSB5cVmIYA-82aAcGiFshPNf3DzUOXQizYu4kqE=\" rel=\"nofollow\" target=\"_blank\">www.relaytx.com<\/a>\u00a0or\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=p-F9LxMZaUtRe67fmdpFa67dmqKJEkiHVnVqBk9j1TM3DJRIjwWTFzgJga1nQrrDCOqZb9vX83mUJbOs7u3cOr9DPp7TfI8teU-JwcRXsG47vkRkB-_5N8D7P98174nBnNpCt5A83xrlaA2i4M2vGH5rJN_KMmeTbVk1_5hKv1GdBTB1MIRwyPz2yvf0CQnq41gdIqiynLN39R4S3NcS8g==\" rel=\"nofollow\" target=\"_blank\">follow us on LinkedIn<\/a>.<\/p>\n<p align=\"left\">\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Pete Rahmer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DFfpSZhOrvDrp0ACP3314yBQ49I08KzUpVWcKHh7HGZ9_LNQqhQaYxsX9qLrjCdEcQ53RbdF_9HRN0bkl8zG3gw7jcQYSfdRNfzg2wM0_rc=\" rel=\"nofollow\" target=\"_blank\">prahmer@relaytx.com<\/a><\/p>\n<p align=\"left\">\n        <strong>Media:<\/strong><br \/>\n        <br \/>Dan Budwick<br \/>1AB<br \/>973-271-6085<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9Q5A_8XQTJu-lsZNhicIk5YEPdTVAIezPCWXTPwtu3pu3ihtou8GaggVzCr84yB-GoGomlhV6K4NkxnEbnCU-txEBJVYWZ3_lCGmhug1w_s=\" rel=\"nofollow\" target=\"_blank\">dan@1abmedia.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODc5MyM3NDA3NDQyIzIxOTk3ODU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NDEyOGE3NjQtN2NiNy00MDg2LThjZGQtZWExMDA2MGRjNzQ1LTEyMTEzMzgtMjAyNi0wMi0wNC1lbg==\/tiny\/Relay-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) &#8212; Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 10:30 a.m. ET. The fireside chats will be webcast live and may be accessed through Relay Therapeutics\u2019 website under Events in the News &amp; Events section through the following link: https:\/\/ir.relaytx.com\/news-events\/events-presentations. An archived replay of the webcast will be available for up to 30 days following the event. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing\u00a0potentially &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-934201","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) &#8212; Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 10:30 a.m. ET. The fireside chats will be webcast live and may be accessed through Relay Therapeutics\u2019 website under Events in the News &amp; Events section through the following link: https:\/\/ir.relaytx.com\/news-events\/events-presentations. An archived replay of the webcast will be available for up to 30 days following the event. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing\u00a0potentially &hellip; Continue reading &quot;Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-04T21:08:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODc5MyM3NDA3NDQyIzIxOTk3ODU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026\",\"datePublished\":\"2026-02-04T21:08:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\\\/\"},\"wordCount\":258,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODc5MyM3NDA3NDQyIzIxOTk3ODU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\\\/\",\"name\":\"Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODc5MyM3NDA3NDQyIzIxOTk3ODU=\",\"datePublished\":\"2026-02-04T21:08:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODc5MyM3NDA3NDQyIzIxOTk3ODU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODc5MyM3NDA3NDQyIzIxOTk3ODU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\/","og_locale":"en_US","og_type":"article","og_title":"Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) &#8212; Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 10:30 a.m. ET. The fireside chats will be webcast live and may be accessed through Relay Therapeutics\u2019 website under Events in the News &amp; Events section through the following link: https:\/\/ir.relaytx.com\/news-events\/events-presentations. An archived replay of the webcast will be available for up to 30 days following the event. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing\u00a0potentially &hellip; Continue reading \"Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-04T21:08:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODc5MyM3NDA3NDQyIzIxOTk3ODU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026","datePublished":"2026-02-04T21:08:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\/"},"wordCount":258,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODc5MyM3NDA3NDQyIzIxOTk3ODU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\/","name":"Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODc5MyM3NDA3NDQyIzIxOTk3ODU=","datePublished":"2026-02-04T21:08:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODc5MyM3NDA3NDQyIzIxOTk3ODU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODc5MyM3NDA3NDQyIzIxOTk3ODU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relay-therapeutics-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/934201","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=934201"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/934201\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=934201"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=934201"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=934201"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}